OSMI-1: A Selective O-GlcNAc Transferase Inhibitor for Research

Executive Summary: OSMI-1 is a small molecule inhibitor that selectively targets O-GlcNAc transferase (OGT) with an IC₅₀ of 2.7 μM, enabling reduction of protein O-GlcNAcylation in cellular and animal models (source: product_spec). In vitro, 50 μM OSMI-1 reduces CHO cell viability by ~50% after 24 hours, demonstrating cytotoxic potential under these conditions (source: product_spec). In vivo, zebrafish LC₅₀ values are 0.031 mg/mL (12h) and 0.025 mg/mL (24h), indicating moderate acute toxicity (source: product_spec). OSMI-1 has high purity (>98%), is soluble in DMSO, and is supplied by APExBIO for O-GlcNAcylation research. Recent literature demonstrates the importance of O-GlcNAc modification in regulating ferroptosis and trophoblast function—a field where OSMI-1 is an essential tool (source: DOI).

Biological Rationale

O-GlcNAcylation is a dynamic post-translational protein modification that modulates numerous cellular processes, including stress responses, nutrient sensing, and cell fate determination. Aberrant O-GlcNAcylation is implicated in diseases such as cancer, diabetes, neurodegeneration, and preeclampsia (source: DOI). In placental biology, O-GlcNAc modification stabilizes the E3 ligase HUWE1, which catalyzes the ubiquitination and degradation of transferrin receptor 1 (TfR1), thereby limiting iron uptake and ferroptosis during trophoblast syncytialization. Pharmacological modulation of O-GlcNAcylation, made possible by selective OGT inhibitors like OSMI-1, provides a mechanistic entry point for dissecting these pathways (source: internal_link; this article expands by detailing OSMI-1's practical parameters and evidence base).

Mechanism of Action of OSMI-1

OSMI-1 is a cell-permeable, small molecule OGT inhibitor. It binds to OGT and blocks its enzymatic activity, preventing the transfer of N-acetylglucosamine (GlcNAc) to serine/threonine residues on nuclear and cytoplasmic proteins. This results in decreased global O-GlcNAcylation, as evidenced by loss of O-GlcNAc-modified Nup62 mass shifts in cell lysates (source: product_spec). OSMI-1 also leads to decreased levels of O-GlcNAcase (OGA), potentially via feedback or compensation mechanisms. As a DMSO-soluble compound (≥50.6 mg/mL), OSMI-1 is amenable for in vitro and in vivo use, but is insoluble in ethanol and water, limiting formulation options (source: product_spec).

Evidence & Benchmarks

• OSMI-1 exhibits an IC₅₀ of 2.7 μM for OGT inhibition in biochemical assays (source: product_spec).
• Treatment with 50 μM OSMI-1 results in approximately 50% reduction in CHO cell viability at 24h, highlighting cytotoxicity at high concentrations (source: product_spec).
• In zebrafish, the LC₅₀ is 0.031 mg/mL (56 μM) at 12h and 0.025 mg/mL (45 μM) at 24h, demonstrating moderate acute toxicity in vivo (source: product_spec).
• OSMI-1 is supplied at >98% purity, validated by HPLC and NMR (source: product_spec).
• O-GlcNAc modification of HUWE1 regulates TfR1 ubiquitination, impacting ferroptosis and trophoblast syncytialization in preeclampsia (source: DOI).
• Elevation of O-GlcNAcylation level ameliorates iron overload-induced preeclamptic phenotypes in animal models (source: DOI).

For an expanded discussion on OSMI-1's protocol nuances and troubleshooting for O-GlcNAcylation research, see "OSMI-1: Precision OGT Inhibition for Decoding O-GlcNAcylation". This article supplies additional details on workflow integration that are summarized and updated here.

Applications, Limits & Misconceptions

OSMI-1 is employed in O-GlcNAcylation research, protein O-GlcNAc modification studies, and mechanistic investigations of ferroptosis, mitochondrial homeostasis, and syncytialization. By enabling acute and reversible OGT inhibition, it is a key tool for dissecting the temporal roles of O-GlcNAc in cell signaling and stress adaptation (source: internal_link; this article provides updated purity, storage, and toxicity specifications not detailed elsewhere).

Common Pitfalls or Misconceptions

• OSMI-1 is not effective in ethanol- or water-based formulations due to insolubility (source: product_spec).
• High concentrations (≥50 μM) may induce off-target cytotoxicity and should be titrated for each cell line (source: product_spec).
• Long-term storage of OSMI-1 solutions is not recommended due to reduced stability; use freshly prepared aliquots (source: product_spec).
• OSMI-1 modulates both OGT and, indirectly, OGA levels, which may confound interpretation of O-GlcNAc cycling (source: product_spec).
• OSMI-1's in vivo toxicity profile is model-dependent and should not be directly extrapolated between species without empirical validation (source: workflow_recommendation).

For a focused review on OSMI-1's cellular constraints and evidence boundaries, see "OSMI-1: Cell-Permeable O-GlcNAc Transferase Inhibitor, Evidence & Limits"; here, we provide updated in vivo data and storage recommendations.

Workflow Integration & Parameters

Protocol Parameters

• assay: OGT enzymatic inhibition | value_with_unit: IC₅₀ = 2.7 μM | applicability: in vitro enzyme assays | rationale: quantifies selective potency | source_type: product_spec
• assay: Cell viability (CHO cells) | value_with_unit: 50% reduction at 50 μM, 24h | applicability: cytotoxicity screen | rationale: defines upper limit for cell-based experiments | source_type: product_spec
• assay: In vivo toxicity (zebrafish) | value_with_unit: LC₅₀ = 0.025–0.031 mg/mL at 12–24h | applicability: acute toxicity assessment | rationale: informs safe concentration range | source_type: product_spec
• assay: Solubility | value_with_unit: ≥50.6 mg/mL in DMSO | applicability: stock preparation | rationale: maximizes working concentration for dosing | source_type: product_spec
• assay: Storage | value_with_unit: -20°C, blue ice shipping | applicability: reagent stability | rationale: preserves compound integrity | source_type: product_spec
• assay: O-GlcNAcylation proteomics | value_with_unit: variable | applicability: downstream effect readout | rationale: links OGT inhibition to protein modification changes | source_type: DOI
• assay: OGA quantification | value_with_unit: decrease post-treatment | applicability: interpret off-target effects | rationale: OGT-OGA interdependence | source_type: product_spec

For detailed protocol optimization and troubleshooting, consult the OSMI-1 product page and the referenced internal reviews for workflow recommendations.

Conclusion & Outlook

OSMI-1, available from APExBIO, is a validated, high-purity, cell-permeable O-GlcNAc transferase inhibitor enabling precise research into O-GlcNAcylation, ferroptosis, and placental biology. Its defined activity, selectivity, and toxicity parameters make it a standard in mechanistic studies. Future research will further delineate O-GlcNAc modification’s roles in disease, leveraging robust tools like OSMI-1 for molecular dissection. The therapeutic implications of modulating O-GlcNAcylation, particularly in reproductive and metabolic disorders, remain a promising avenue for investigation, as underscored by recent discoveries in preeclampsia models (source: DOI).